logo-loader

Sareum Holdings raises over a £1mln to advance preclinical work on its TYK2/JAK1 drugs

Published: 10:51 04 Jun 2020 BST

Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802.

Mitchell says they're exploring the potential benefit of the TYK2/JAK1 inhibitors against coronavirus (COVID-19) as well as in cancer and autoimmune diseases.

Preparatory work is being made to advance candidates towards human trials.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

39 minutes ago